Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

NCT02740270 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphomas

Interventions

DRUG: GWN323
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals